Gemcitabin is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). The most-studied condition is Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
NCT07466238 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)
|
Not applicable | Recruiting | Peking University | China |
|
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
NCT07480850 · ClinicalTrials.gov ↗ · Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
|
Phase 2 | Active, closed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Peking University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Gemcitabin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) and Peking University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gemcitabin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.